Sound Waves Over Scalpels: Cardiawave’s Quiet Revolution in Heart Care

LEVALLOIS-PERRET, France – June 15, 2026 – In the world of cardiovascular medicine, the dominant narrative for decades has been one of replacement. A failing heart valve meant a high-stakes surgical procedure to swap it out. But a French medtech pioneer, Cardiawave, is now deploying a technology that fundamentally challenges that paradigm. Its Valvosoft® device, which just began routine use in hospitals across France, Germany, and the Netherlands, doesn't replace the valve. It repairs it—non-invasively, using nothing more than focused ultrasound.

This move from a product-based solution (a new valve) to a service-based one (restoring the native valve) represents a profound operational innovation in a multi-billion-dollar market. Following its CE Mark approval in late 2025, Cardiawave is transitioning from a clinical-stage company to a commercial force, targeting a vulnerable patient population that the surgical revolution left behind. For investors and healthcare leaders, this isn't just a new device; it's the opening move in a strategic play to redefine the treatment continuum for one of the most common cardiac conditions in the elderly.

A New Tool for an Untreated Population

Aortic stenosis, a progressive calcification and stiffening of the heart's main exit valve, is a grim diagnosis. Affecting an estimated 12.4% of people over 75, the severe, symptomatic form of the disease carries a life expectancy of just over two years without intervention. The established solutions are effective but invasive: Surgical Aortic Valve Replacement (SAVR), which is open-heart surgery, and the less invasive Transcatheter Aortic Valve Replacement (TAVR).

Yet, a significant subset of patients—estimated by Cardiawave to be around 300,000 in Europe and the US—are ineligible for or decline these procedures due to frailty, comorbidities, or other risks. For them, the prognosis has been bleak. Valvosoft® was designed specifically for this group.

The technology is an elegant application of physics to medicine. Using high-intensity ultrasound pulses, the device precisely targets and fragments the calcium deposits on the valve leaflets, restoring their flexibility and allowing the valve to open more freely. The procedure is performed without general anesthesia or any incision, preserving the patient’s native valve and avoiding the complications associated with implants.

"Valvosoft® introduces a unique approach: restoring the mobility of the native valve without surgery or implantation," said Professor Emmanuel Messas, an interventional cardiologist at HEGP in Paris and a clinical investigator for the device. He noted that results from clinical studies involving 100 patients across 12 European centers "confirm the feasibility, efficacy, and safety of this non-invasive therapy for patients who previously had no therapeutic option available." Those studies demonstrated not only the therapy's safety but its sustained impact, with patients showing improved cardiac function and quality of life a year after treatment.

The Strategic Deployment

With CE Mark approval secured, Cardiawave is executing a carefully planned commercial rollout. The initial launch in France, the Netherlands, and Germany serves as a beachhead in Europe’s largest medtech markets. The company is simultaneously negotiating distribution agreements to expand its reach across Europe, the UK, the Middle East, and India. This isn't a scattergun approach; it's a targeted strategy to establish a foothold before making a larger global push.

That larger push has its sights set firmly on the lucrative U.S. market. The company is actively preparing an Investigational Device Exemption (IDE) application for the FDA, a critical and capital-intensive step toward commercialization in the United States. Success there would grant access to the world’s largest healthcare market and solidify Valvosoft® as a global standard of care.

This ambition is backed by a clear operational plan. Cardiawave is scaling up its manufacturing capabilities in partnership with French industrial firms and has launched a new financing round. This funding will not only accelerate the production of Valvosoft® systems but also support the costly U.S. clinical studies and fuel research into new therapeutic applications for its ultrasound platform.

"This achievement also marks Cardiawave’s transition into a new phase of growth, driven by the deployment of Valvosoft® across several European countries and our ambition to become a leading player in the non-invasive treatment of aortic stenosis," stated Carine Schorochoff, Cardiawave's Chief Executive Officer.

Reshaping the Lifetime Management of Heart Disease

The immediate market for Valvosoft® is the high-risk patient population with no other options. However, the true long-term potential of this operational innovation lies in its ability to shift treatment to an earlier stage. The company has noted the technology could eventually benefit several million patients with moderate forms of aortic stenosis, potentially delaying or even preventing the need for eventual valve replacement.

This aligns with a growing trend in cardiology toward "lifetime management" of valvular heart disease. By offering a low-risk, repeatable intervention, Valvosoft® could become a tool used to manage the disease's progression over many years, much like medication is used for chronic conditions. It transforms the treatment from a single, high-impact event into a managed process.

For hospitals, the business model is flexible, incorporating system sales, leasing, and per-procedure fees, lowering the barrier to adoption. For patients, it offers the prospect of improved heart function and quality of life without the trauma and recovery time of major surgery. As the first Valvosoft® systems hum to life in European heart centers, they are doing more than just treating a handful of patients; they are broadcasting a clear signal that the way we think about and manage structural heart disease is beginning to change.